Merck KGaA/€MRK
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Merck KGaA
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Ticker
€MRK
Sector
Primary listing
XETRA
Employees
63,160
Headquarters
Website
Merck KGaA Metrics
BasicAdvanced
€50B
17.44
€6.59
0.61
€2.20
1.91%
Price and volume
Market cap
€50B
Beta
0.61
52-week high
€158.70
52-week low
€100.65
Average daily volume
20K
Dividend rate
€2.20
Financial strength
Current ratio
1.237
Quick ratio
0.654
Long term debt to equity
22.236
Total debt to equity
33.19
Dividend payout ratio (TTM)
36.29%
Interest coverage (TTM)
17.75%
Profitability
EBITDA (TTM)
5,953
Gross margin (TTM)
58.69%
Net profit margin (TTM)
13.49%
Operating margin (TTM)
20.08%
Effective tax rate (TTM)
20.99%
Revenue per employee (TTM)
€340,000
Management effectiveness
Return on assets (TTM)
5.48%
Return on equity (TTM)
10.10%
Valuation
Price to earnings (TTM)
17.44
Price to revenue (TTM)
2.353
Price to book
1.77
Price to tangible book (TTM)
9.39
Price to free cash flow (TTM)
27.754
Free cash flow yield (TTM)
3.60%
Free cash flow per share (TTM)
4.141
Dividend yield (TTM)
1.91%
Forward dividend yield
1.91%
Growth
Revenue change (TTM)
1.67%
Earnings per share change (TTM)
9.29%
3-year revenue growth (CAGR)
0.42%
10-year revenue growth (CAGR)
5.71%
3-year earnings per share growth (CAGR)
-4.71%
10-year earnings per share growth (CAGR)
9.54%
3-year dividend per share growth (CAGR)
5.95%
10-year dividend per share growth (CAGR)
8.20%
What the Analysts think about Merck KGaA
Analyst ratings (Buy, Hold, Sell) for Merck KGaA stock.
Bulls say / Bears say
Merck KGaA raised its full-year organic adjusted EBITDA growth guidance to 4%–8%, up from 2%–7%, underscoring strong performance in its pharmaceuticals and laboratory equipment sectors (Reuters)
In Q1 2025, Merck KGaA reported adjusted EBITDA of €1.54 billion, a 5.6% increase that exceeded analysts’ €1.51 billion forecast, demonstrating resilient profitability (Reuters)
The planned $3.9 billion acquisition of SpringWorks Therapeutics is expected to immediately add revenue, expand Merck’s rare tumor portfolio, and be accretive to earnings per share by 2027 (Reuters)
Merck KGaA issued a more cautious full-year adjusted EBITDA outlook of €5.8 billion–€6.4 billion, down from €6.1 billion–€6.6 billion, citing macroeconomic and foreign-exchange uncertainties (Reuters)
Strong negative currency effects weighed on Q2 performance, with FX headwinds cutting net sales by 4.2% and reducing adjusted EBITDA by 7.2% year-over-year (Merck KGaA Q2 2025 Results)
The acquisition of SpringWorks, while strategic, was framed as necessary to counterbalance pipeline weaknesses after recent experimental drug failures and looming patent cliffs, reflecting underlying R&D risks (FT)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Merck KGaA Financial Performance
Revenues and expenses
Merck KGaA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Merck KGaA stock?
Merck KGaA (MRK) has a market cap of €50B as of October 23, 2025.
What is the P/E ratio for Merck KGaA stock?
The price to earnings (P/E) ratio for Merck KGaA (MRK) stock is 17.44 as of October 23, 2025.
Does Merck KGaA stock pay dividends?
Yes, the Merck KGaA (MRK) stock pays dividends to shareholders. As of October 23, 2025, the dividend rate is €2.2 and the yield is 1.91%. Merck KGaA has a payout ratio of 36.29% on a trailing twelve-month basis.
When is the next Merck KGaA dividend payment date?
The next Merck KGaA (MRK) dividend payment date is unconfirmed.
What is the beta indicator for Merck KGaA?
Merck KGaA (MRK) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.